Table 4 Characteristics of esophageal carcinoma patients with or without Atrial fibrillation

Sex

Female

174(15.7%)

8(12.7%)

0.72

Male

937(84.3%)

55(87.3%)

Race

non-White

143(12.9%)

3(4.8%)

0.07

White

968(87.1%)

60(95.2%)

BMI

≤25

271(29.1%)

14(24.1%)

0.45

>25

660(70.9%)

44(75.9%)

Age (years)

≤64

601(54.1%)

12(19%)

<0.01

>64

510(45.9%)

51(81%)

Heavy alcohol use history

No

868(78.3%)

54(85.7%)

0.21

Yes

241(21.7%)

9(14.3%)

Smoke at diagnosis

No

869(78.5%)

53(84.1%)

0.34

Yes

238(21.5%)

10(15.9%)

KPS

≤70

107(9.6%)

10(15.9%)

0.13

>70

1004(90.4%)

53(84.1%)

Tumor histology

ADC

864(79.2%)

50(79.4%)

1.00

SCC

227(20.8%)

13(20.6%)

Tumor location

Upper/middle

152(13.7%)

7(11.1%)

0.71

Low

959(86.3%)

56(88.9%)

Tumor differentiation

Well/moderate

487(44.4%)

30(47.6%)

0.70

Poor

611(55.6%)

33(52.4%)

Tumor length (cm)

≤5

564(57.7%)

35(59.3%)

0.89

>5

414(42.3%)

24(40.7%)

Clinical stage

I-II

403(37.2%)

28(44.4%)

0.28

III-IV

680(62.8%)

35(55.6%)

Surgery

No

567(51%)

47(74.6%)

<0.01

Yes

544(49%)

16(25.4%)

Radiation modality

3DCRT

456(41%)

13(20.6%)

<0.01

IMRT/proton

655(59%)

50(79.4%)

Induction chemotherapy

No

662(59.6%)

44(69.8%)

0.11

Yes

449(40.4%)

19(30.2%)

CRT complete response

No

658(62.3%)

47(77%)

0.02

Yes

399(37.7%)

14(23%)

Chemotherapy after relapse

No

948 (85.3%)

56 (88.9%)

0.58

Yes

163 (14.7%)

7 (11.1%)

Local/regional failure rate

No

298(30.5%)

17(33.3%)

0.64

Yes

678(69.5%)

34(66.7%)

Distant failure rate

No

556(54.9%)

38(73.1%)

0.01

Yes

456(45.1%)

14(26.9%)